Clinical Trials Browser

Colonic Neoplasms

NCT07405086 2026-05-22

Morning Versus Afternoon Administration of Immunotherapy for the Treatment of Advanced or Metastatic Solid Tumors, The Knight SHIFT Study

DermatologicGastrointestinalGenitourinaryHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Hepatocellular, Lung Neoplasms, Melanoma, Neoplasm Metastasis

Clinical Trials

OPTICAL-3

Morning Versus Afternoon Administration of Immunotherapy for the Treatment of Advanced or Metastatic Solid Tumors, The Knight SHIFT Study

PIPO

RAIRI-NPC

[18F]FTT Positron Emission Tomography for the Measurement of PARP Tumor Expression in Patients With Metastatic Breast Cancer

Study of PULSAR-ICI +/- IMSA101 in Patients With Oligoprogressive Solid Tumor Malignancies

Safety and Tolerability of Low Dose Radiotherapy Concurrent SBRT and PD-1 Inhibitors in Advanced NSCLC.

IC Plus Low-dose Radiation Plus Cadonilimab in LANPC

Neoadjuvant ICI and Mitochondrial Vaccine for Resectable HNSCC

Safety and Efficacy of Whole Brain LDRT+ICI+Intrathecal Chemotherapy in Refractory Meningeal Metastasis of Lung Cancer

HAIC Plus Systemic Therapy as De-escalation Therapy Strategy for Biliary Tract Cancer

MELCHRONO: A Prospective Randomized Study Investigating Chrono-immunotherapy for Advanced Melanoma.

DOMISOL

Chidamide Combined With Chemotherapy and Immunotherapy as First-line Treatment for Advanced Intrahepatic Cholangiocarcinoma

Safety and Tolerability of LDRT Plus Concurrent Partial SBRT and Tislelizumab in Patients With Bulky Tumors

Conversion Therapy Plus Surgery and Radiotherapy for Retroperitoneal Nodal Metastases in Gastric Cancer

Chase

USZ-STRIKE

Clinical Study of GT201 in Combination With PD-1 Inhibitor for Advanced Head and Neck Tumors

TORCH-STAR

PD1-VEN-CAG

CCRT Followed by PD-1 Inhibitor Maintenance Therapy in Locally Advanced ESCC

ICI-Vasc

INS-ESCC-CT

TORCH-iTNT

Using Healthy Gut Bacteria to Boost Immune Treatment for Advanced Bowel Cancer

Effect of Tumor Treating Fields (TTFields) (150 kHz) Concurrent With Standard of Care Therapies for Treatment of Stage 4 Non-small Cell Lung Cancer (NSCLC) Following Platinum Failure (LUNAR)

rHSC-DIPGVax Plus Checkpoint Blockade for the Treatment of Newly Diagnosed DIPG and DMG

Mechanism of Enhanced Efficacy of Ivonescimab in Neoadjuvant Therapy for Non-Small Cell Lung Cancer

HAIC Plus Lenva and PD-1 for Advanced HCC With Macrovascular or Biliary Invasion

TRIUNITE-08

Priming Immunotherapy in Advanced Disease With Radiation

Impact of Postoperative Radiotherapy Versus PD-1 Inhibitor Maintenance on Survival in Resectable Locally Advanced Oral and Oropharyngeal Squamous Cell Carcinoma

Neoadjuvant Chemotherapy and PD-1 Inhibitor for Locally Advanced Rectal Cancer（CONTROL-01）

Immune-Related Adverse Events After Cancer Immunotherapy and Safety of Treatment Rechallenge

CIML NK Cell in Head & Neck Cancer

JACKPOT38

Polarized Dendritic Cell (aDC1) Based Treatment, Interferon Alpha-2, Rintatolimod, and Celecoxib for the Treatment of HLA-A2+ Refractory Melanoma

PRISM-TNBC

MINER2

Gastrointestinal Microbiome and Response to Immunotherapy in Metastatic Malignant Melanoma

A Study of Liposomal Irinotecan Plus 5-FU/LV HAIC With Lenvatinib and a PD-1 Inhibitor in Advanced ICC

A Real-World Study Evaluating the Efficacy and Safety of Adebrelimab in Patients With Advanced SCLC

SARCO-CTI

MINER

Predictive Biomarkers for Pneumonitis After Chemoradiotherapy and Immunotherapy in Patients With Non-small Cell Lung Cancer

iFOCUS

Lenvatinib Plus PD-1 Inhibitor for Advanced Solid Tumors With 11q13 Amplification

SKY

Exercise to Boost Response to Checkpoint Blockade Immunotherapy